Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2015 Results
Get Alerts SGNT Hot Sheet
Join SI Premium – FREE
SCHAUMBURG, Ill., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 third quarter pre-market on Tuesday, November 3, 2015 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Interested parties may access the live call by dialing:
Within the United States: 877-293-5456International: 707-287-9357
A live webcast of the teleconference will be available on the company's website at: http://investor.sagentpharma.com/events.cfm.
A replay of the presentation will be available on the Sagent website or by dialing:
Toll-Free: 855-859-2056Passcode: 61642359
The replay will be available until November 16, 2015.
About Sagent Pharmaceuticals, Inc.Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 [email protected]Source: Sagent Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!